Vuk Milorad Aleksić

Dr. Vuk Milorad Aleksić


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VAVuk Milorad Aleksić
Vuk Milorad Aleksić
JTJovana Todorović
Jovana Todorović
NMNenad Miladinović
Nenad Miladinović
NANemanja Aleksić
Nemanja Aleksić
VBVojislav Bogosavljević
Vojislav Bogosavljević
MJMiloš Joković
Miloš Joković
The normal ligamentum flavum (LF) is a well-defined elastic structure with specific innervation. Several studies investigated LF in patients with lumbar spinal stenosis (LSS) and used lumbar discus hernia (LDH) patients as control group, only on the presumed thesis that LF in this patients have normal morphology. In patients with LSS thickening of the LF is the main cause of stenosis, which is most often presented with neurogenic claudication, whose pathophysiological mechanism is not completely understood. We conducted observational cohort study of 60 operated patients divided into two groups. The first group of 30 patients underwent micro-discectomy (LSH group), and second group with 30 patients underwent decompression, after which analysis of harvested LF was performed. Patients from the LDH group and LSS group differed significantly in the frequencies of chief complaints, duration of symptoms, physical examination, and specific morphological/radiological parameters. The LF analysis showed that the groups differed significantly in the amount of collagen and elastic fibers, as well as in the histological appearance/architectonics of elastic fibers. Also, groups differ in the presence of LF nerve fibers. Our findings speak in favor of the recently postulated inflammatory theory in the origin of spinal neurogenic claudication’s.

13 December 2011 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
Uros BumbasirevicUros Bumbasirevic
Uros Bumbasirevic
DDDejan Dragicevic
Dejan Dragicevic
AJAleksandar Janicic
Aleksandar Janicic
VCVesna Cemerikic-Martinovic
Vesna Cemerikic-Martinovic
MCMilica Cekerevac
Milica Cekerevac
CTCane Tulic
Cane Tulic
Wegener's granulomatosis (WG) is a systemic disorder characterized by necrotizing vasculitis involving the respiratory tract, and in most cases, the kidneys. The most common manifestation of WG in the kidneys is segmental necrotizing glomerulonephritis. The presence of a renal mass as a manifestation of WG is rare. We report a patient with WG in whom a CT scan revealed an infiltrating mass in the lower portion of the left kidney. After surgical exploration, we performed an open radical nephrectomy. Histopathology showed clear cell type renal cell carcinoma (RCC). RCC associated with WG has been reported in only a few cases, and in most of them, the diseases started simultaneously, suggesting common pathogenetic pathways. Long-term immunosuppressive treatment is a known risk factor in the development of malignancies, so occurrence of RCC in WG has been proposed as a side effect of cyclophosphamide treatment. Furthermore, it is important to make a differential diagnosis between RCC and pseudotumors in WG as they cannot be distinguished solely on basis of imaging findings. Due to the higher risk of urologic malignancies, more frequent checkups and screening of WG patients should be considered.

1 November 2021 in Neurocirugia
Verified
Journal Article
Closed access
VAVuk Milorad Aleksić
Vuk Milorad Aleksić
MJMiloš Joković
Miloš Joković
RIRosanda Ilić
Rosanda Ilić
VBVojislav Bogosavljević
Vojislav Bogosavljević
BĐBranko Đurović
Branko Đurović

12 April 2025 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
MMMilija Mijajlovic
Milija Mijajlovic
NBNatan M. Bornstein
Natan M. Bornstein
VAVuk Milorad Aleksić
Vuk Milorad Aleksić
Stroke remains a major global health concern, ranking as the second most common cause of death and the third leading cause of disability worldwide. Despite advances in therapy and management, ischemic stroke patients continue to face high risks of recurrence, cardiovascular events, and mortality. Effective secondary stroke prevention is critical, encompassing antithrombotic therapy, management of vascular risk factors such as hypertension, dyslipidemia, and diabetes mellitus, and conducting healthy lifestyle. Approximately 80% of strokes are ischemic, with a significant proportion attributable to large-artery atherosclerosis of the extra- and intracranial arteries, particularly in the internal carotid artery. Atherothrombotic strokes, linked to plaque rupture and thrombus formation, present a notably high risk of recurrence. Inflammatory and immune mechanisms play pivotal roles in both the initiation and progression of atherosclerosis and stroke. Colchicine, an anti-inflammatory agent, has shown potential in managing cardiovascular disease, though its effects on stroke reduction and prevention have been inconsistent across studies. Its possible protective role against stroke is attributed to its anti-inflammatory actions, which include disrupting microtubule dynamics, inhibiting immune cell movement, and lowering inflammatory markers like L-Selectin and E-Selectin, while also suppressing interleukin release. Glucagon-like peptide-1 receptor agonists (GLP-1RA) agents have emerged as effective therapies for type 2 diabetes with notable cardiovascular benefits. These agents enhance glucose control while also providing protective effects against atherosclerosis and stroke. GLP-1RA drugs work by mimicking the effects of GLP-1, a peptide that regulates insulin release and glucose metabolism. They also exhibit anti-inflammatory properties, potentially reducing stroke risk through mechanisms such as improved endothelial function and reduced plaque formation. Clinical trials have indicated that GLP-1RA agents can significantly lower the incidence of nonfatal strokes and major adverse events. This narrative review underscores the importance of targeting inflammation to reduce the risk of recurrent stroke, emphasizing recent studies on colchicine and GLP-1RA. It consolidates evidence regarding the efficacy of these agents in secondary stroke prevention; however, future studies are needed to further explore their mechanisms and roles in comprehensive stroke management strategies.

1 January 2019 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
DSDejan Stevanovic
Dejan Stevanovic
VAVuk Milorad Aleksić
Vuk Milorad Aleksić
DSDragos Stojanovic
Dragos Stojanovic
NMNebojsa Mitrovic
Nebojsa Mitrovic
DJDamir Jasarovic
Damir Jasarovic
ZBZorana Bokun-Vukasinovic
Zorana Bokun-Vukasinovic
Introduction. Osseous metaplasia is a heterotopic formation of bone and its appearance in benign gastrointestinal polyps is exceedingly rare. The mechanism responsible for this type of metaplasia is not fully understood, however it seems to be an innocent rare phenomenon. Case outline. We present a case of a 31-year-old male with mesenchimal osseal metaplasia in a large inflamatory polyp measuring 57 ? 23 ? 20 mm in diameter, located in the anal canal region. Conclusion. According to our knowledge, this is the largest gastrointestinal polyp with osseous metaplasia described so far. Although a rare phenomenon, there are certain characteristics of this disease, so we conducted a literature review and summarized these characteristics.

1 January 2013 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
APAleksandra M Pavlovic
Aleksandra M Pavlovic
DPDragan Pavlovic
Dragan Pavlovic
VAVuk Milorad Aleksić
Vuk Milorad Aleksić
NSNadezda Sternic
Nadezda Sternic
Vascular dementia (VaD) is the second most frequent dementia after Alzheimer?s disease, and is diagnosed during lifetime in 20% of demented patients. Five?year survival rate in VaD is 39%, while it is estimated to be 75% in healthy persons of the same age. It is therefore important to make correct diagnosis of VaD early in the course of the disease. Risk factors for VaD are identical to stroke risk factors, and there are significant possibilities for the prevention of vascular cognitive decline. Cognitive decline develops acutely or step?by?step within three months after stroke, but more gradual progression of intellectual decline is also possible. Neurological examination can reveal pyramidal and extrapyramidal signs, pseudobulbar palsy, gait disturbance and urinary incontinence. Neuropsychological profile comprises the loss of cognitive set shifting, decline in word fluency, verbal learning difficulties, perseverations, difficulties in complex figure copying, and in patients with cortically located lesions also problems with speech and praxia. The basis of the diagnosis is, besides history, neurological examination and neuropsychological assessment, computed tomography and/ or magnetic resonance brain imaging. Vascular risk factors control is the most important measure in VaD prevention. Modern guidelines for the treatment of cognitive decline in VaD emphasize that donepezil can be useful in the improvement of cognitive status at the level of Class IIa recommendation at the level of evidence A, while memantine may be useful in patients with mixed VaD and Alzheimer?s disease dementia.